Bradykinin
Bradykinin is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
68 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Angioedema | D000799 | EFO_0005532 | T78.3 | 1 | 4 | 2 | 1 | 9 | 17 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 2 | 3 | 5 |
| Ischemic stroke | D000083242 | — | — | — | 1 | — | 1 | 1 | 3 |
| Prehypertension | D058246 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hereditary angioedemas | D054179 | EFO_0004131 | — | — | 3 | 5 | — | 2 | 9 |
| Hereditary angioedema types i and ii | D056829 | — | — | — | 3 | 2 | — | 1 | 5 |
| Inflammation | D007249 | MP_0001845 | — | — | 2 | 1 | — | 1 | 3 |
| Covid-19 | D000086382 | — | U07.1 | — | 2 | 1 | — | 1 | 3 |
| Hereditary angioedema type iii | D056828 | — | — | — | 1 | 2 | — | — | 2 |
| Cardiopulmonary bypass | D002315 | — | — | — | 1 | 1 | — | — | 1 |
| Fibrinolysis | D005342 | — | — | — | 1 | 1 | — | — | 1 |
| Hypotension | D007022 | EFO_0005251 | I95 | — | — | 1 | — | — | 1 |
| Neck pain | D019547 | — | M54.2 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | — | I25.1 | 1 | 1 | — | — | 2 | 4 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | — | — | 2 | 3 |
| Coronary disease | D003327 | — | — | — | 1 | — | — | 1 | 2 |
| Vasculitis | D014657 | EFO_0006803 | M31 | — | 2 | — | — | — | 2 |
| Cerebrovascular disorders | D002561 | EFO_0003763 | I60-I69 | — | 1 | — | — | — | 1 |
| Impacted tooth | D014095 | — | K01.1 | — | 1 | — | — | — | 1 |
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | 1 | — | — | — | 1 |
| Hyperlipoproteinemias | D006951 | — | — | — | 1 | — | — | — | 1 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | 1 | — | — | — | 1 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | 2 | 4 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | 2 | 3 |
| Vasodilation | D014664 | — | — | 1 | — | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | — | 1 |
| Medulloblastoma | D008527 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombosis | D013927 | — | — | — | — | — | — | 4 | 4 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | — | 4 | 4 |
| Cough | D003371 | — | R05 | — | — | — | — | 3 | 3 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | — | — | 2 | 2 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 2 | 2 |
| Heart transplantation | D016027 | EFO_0010673 | — | — | — | — | — | 2 | 2 |
| Emergencies | D004630 | — | — | — | — | — | — | 2 | 2 |
| Ulcer | D014456 | MPATH_579 | — | — | — | — | — | 2 | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | — | 1 | 1 |
Show 12 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bradykinin |
| INN | _ |
| Description | Bradykinin is a linear nonapeptide messenger belonging to the kinin group of proteins, with amino acid sequence RPPGFSPFR. Enzymatically produced from kallidin in the blood, it is a powerful vasodilator that causes smooth muscle contraction, and may mediate inflammation. It has a role as a human blood serum metabolite and a vasodilator agent. It is a tautomer of a bradykinin(2+). |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N=C(N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 58-82-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL406291 |
| ChEBI ID | 3165 |
| PubChem CID | 439201 |
| DrugBank | — |
| UNII ID | S8TIM42R2W (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use